In The News
Johnson & Johnson hit with class action over cold and flu medications
ASIC, Noumi win appeal in privilege fight over PwC report
‘In all circumstances unconscionable’: ASIC wins case against forex broker
Limitations defences not relevant to new claims in Victoria class actions, court told
Graincorp class action seeks to bring toxicity claims
Last innings for retiring appeal judge who ‘leaves a great legacy’
Investor class action against Linchpin insurer AIG prevails
Judge approves $57.5M ANZ class action settlement, funder’s ATE costs
ACCC shuts lawyers for cartel immunity seekers out of the room
AGL cops a $25M penalty for overcharging welfare recipients
Please login to bookmarkClose

Samsung Bioepis can’t get indemnity costs from Janssen Biotech after it surrendered patents for Crohn’s disease drug Stelara and filed a fresh case based on new patents for the drug. 

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au